IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for ...

A new pathway to fast track patients from the Preston area with suspected ovarian cancer is being implemented at the Royal ...

A nurse, foster mom and the primary provider for a family of eight, Shelly Sepulveda has devoted her life to taking care of ...

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...

A new resource from the National Comprehensive Cancer Network (NCCN) provides evidence-based guidance on assessing and ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...

The Ovarian Cancer Research Alliance (OCRA) proudly announces the extraordinary success of its 2024 year-end fundraising campaign, surpassing its $2 million goal and marking a transformative milestone ...

There are other ways to evaluate ovarian cancer patients beyond radiology ... remains responsible for the patient’s diagnosis and treatment." Epstein noted that AI should only be used as a ...

IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.

By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...